Novel Agents for the Treatment of Low/Intermediate Risk Myelodysplastic Syndromes
Risk Stratification in MDS
MDS Risk Assessment: IPSS vs IPSS-R
Risk Assessment Remains a Challenge
Link Between Mutations and Comorbidities
Epidemiology of MDS[a]
Not All Patients Require Treatment
Use of Supportive Care Is Individualized
Treatment of Anemia in Lower-Risk MDS
Use of Lenalidomide in Patients with MDS
Luspatercept: A Novel ESA
Imetelstat: A First-in-Class Telomerase Inhibitor
Hypomethylating Agents in Lower-Risk MDS
Other Novel Strategies in MDS
Abbreviations
Abbreviations (cont)